drugset / Trial / NCT06812780

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389

NCT06812780

Phase 1 Completed 35 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.

Timeline

Start
2025-02-04
Primary completion
2025-09-04
Completion
2025-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2389 Small molecule Oral

Indications

No indication recorded.